BACKGROUND: Obstructive sleep apnea syndrome (OSAS) is associated with autonomic dysfunction and metabolic abnormalities including obesity, dyslipidemia, and insulin resistance. Heart rate recovery at 1min after exercise termination (HRR-1) is a marker of vagal tone. We hypothesized that patients with more severe OSAS would have a lower HRR-1, either due to the co-existing metabolic abnormalities or OSAS. METHODS: Sixty-three patients with untreated OSAS (49.2+/-9.8years) without glucose- or lipid-lowering or negatively chronotropic drugs underwent cardiopulmonary exercise testing including HRR-1 measurement and assessment of several metabolic parameters. Patients with severe OSAS (apnea-hypopnea index [AHI]>30h(-1); n=32) were compared to patients with mild to moderate OSAS (AHI 5-30h(-1); n=31). RESULTS: Patients with severe OSAS were more likely to be male (25 vs. 3%; p=0.01) and to have hypertension (72 vs. 39%; p=0.01); they also had higher fasting glucose (5.4+/-0.5 vs. 5.1+/-0.4mmol/l; p=0.016) and C-peptide [905 (651-1353) vs. 749 (597-919)pmol/l; p=0.028] levels compared to patients with mild to moderate OSAS. The groups did not differ with respect to peak heart rate (p=0.2) or peak oxygen consumption (p=0.9), but HRR-1 was significantly lower in patients with severe OSAS compared to patients with mild and moderate OSAS [20 (15-25) vs. 24 (18-34)bpm; p=0.022]. Higher AHI (p=0.01) and lower peak heart rate (p=0.02), but not body mass index or insulin resistance, were independently associated with lower HRR-1. CONCLUSIONS: The severity of OSAS expressed as higher AHI is independently associated with lower HRR-1, a measure of autonomic dysfunction.
BACKGROUND:Obstructive sleep apnea syndrome (OSAS) is associated with autonomic dysfunction and metabolic abnormalities including obesity, dyslipidemia, and insulin resistance. Heart rate recovery at 1min after exercise termination (HRR-1) is a marker of vagal tone. We hypothesized that patients with more severe OSAS would have a lower HRR-1, either due to the co-existing metabolic abnormalities or OSAS. METHODS: Sixty-three patients with untreated OSAS (49.2+/-9.8years) without glucose- or lipid-lowering or negatively chronotropic drugs underwent cardiopulmonary exercise testing including HRR-1 measurement and assessment of several metabolic parameters. Patients with severe OSAS (apnea-hypopnea index [AHI]>30h(-1); n=32) were compared to patients with mild to moderate OSAS (AHI 5-30h(-1); n=31). RESULTS:Patients with severe OSAS were more likely to be male (25 vs. 3%; p=0.01) and to have hypertension (72 vs. 39%; p=0.01); they also had higher fasting glucose (5.4+/-0.5 vs. 5.1+/-0.4mmol/l; p=0.016) and C-peptide [905 (651-1353) vs. 749 (597-919)pmol/l; p=0.028] levels compared to patients with mild to moderate OSAS. The groups did not differ with respect to peak heart rate (p=0.2) or peak oxygen consumption (p=0.9), but HRR-1 was significantly lower in patients with severe OSAS compared to patients with mild and moderate OSAS [20 (15-25) vs. 24 (18-34)bpm; p=0.022]. Higher AHI (p=0.01) and lower peak heart rate (p=0.02), but not body mass index or insulin resistance, were independently associated with lower HRR-1. CONCLUSIONS: The severity of OSAS expressed as higher AHI is independently associated with lower HRR-1, a measure of autonomic dysfunction.
Authors: Felipe X Cepeda; Edgar Toschi-Dias; Cristiane Maki-Nunes; Maria Urbana P B Rondon; Maria Janieire N N Alves; Ana Maria F W Braga; Daniel G Martinez; Luciano F Drager; Geraldo Lorenzi-Filho; Carlos E Negrao; Ivani C Trombetta Journal: Sleep Date: 2015-07-01 Impact factor: 5.849
Authors: Bruno Teixeira Barbosa; Amilton da Cruz Santos; Murillo Frazão; Tulio Rocha Petrucci; Gabriel Grizzo Cucato; Adriana Oliveira Sarmento; Eduardo D S Freitas; Anna Myrna Jaguaribe de Lima; Maria do Socorro Brasileiro-Santos Journal: Sleep Breath Date: 2017-08-24 Impact factor: 2.816
Authors: Kristin J Horsley; Codie R Rouleau; Sheila N Garland; Charles Samuels; Sandeep G Aggarwal; James A Stone; Ross Arena; Tavis S Campbell Journal: J Behav Med Date: 2016-03-05